A5008851608- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cytokine Signaling Pathways and Interactions
- Cancer Immunotherapy and Biomarkers
- Cancer Risks and Factors
- Breast Lesions and Carcinomas
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Peptidase Inhibition and Analysis
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Stress, Anesthesia, and Immune Response
- Inflammatory Biomarkers in Disease Prognosis
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Metabolism, Diabetes, and Cancer
- Intraocular Surgery and Lenses
- Retinal and Macular Surgery
- Multiple and Secondary Primary Cancers
- Immune Cell Function and Interaction
- DNA Repair Mechanisms
- Genetic factors in colorectal cancer
- Metastasis and carcinoma case studies
- Latin American socio-political dynamics
Santa Maria Nuova Hospital
2021-2024
University of Chieti-Pescara
2014-2021
Santissima Trinità
2018
Ospedale SS. Annunziata
2012-2017
Experimental Medicine and Biology Institute
2015-2017
Universidad Nacional de La Plata
2009
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2006
The immune system seems to play a fundamental role in breast cancer responsiveness chemotherapy. We investigated two peripheral indicators of immunity/inflammation, i.e. neutrophil lymphocyte ratio (NLR) and platelet (PLR), order reveal possible relationship with pathological complete response (pCR) patients early or locally advanced treated neoadjuvant chemotherapy (NACT).We retrospectively analyzed 373 consecutive affected by candidates NACT. blood cell count before starting NACT was...
// Patrizia Vici 1 , Laura Pizzuti Andrea Michelotti 2 Isabella Sperduti 3 Clara Natoli 4 Lucia Mentuccia 5 Luigi Di Lauro Domenico Sergi Paolo Marchetti 6 Daniele Santini 7 Emanuela Magnolfi Iezzi Luca Moscetti 8 Agnese Fabbri 9 Alessandra Cassano 10 Antonino Grassadonia Claudia Omarini 11 Federico Piacentini Botticelli Ilaria Bertolini Angelo Fedele Scinto 12 Germano Zampa 13 Maria Mauri 14 Loretta D'Onofrio Valentina Sini Maddalena Barba Marcello Maugeri-Saccà Ernesto Rossi Elisabetta...
Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk recurrence and become standard care for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer patients. Since most data on benefits come from clinical trials, conducted in selected patient populations, we performed a retrospective analysis HER2-positive patients treated "pre-trastuzumab" "trastuzumab" eras, with aim determine patients' outcomes real-world practice. 925 consecutive ten...
We aimed to assess the efficacy of neoadjuvant chemotherapy (NACT) in a cohort 213 triple‐negative breast cancer (TNBC) patients treated real‐world practice at eight Italian centers. computed descriptive statistics for all variable interest. Factors testing significant univariate analysis were included multivariate models. Survival data compared by Kaplan–Meier curves and log‐rank test. The median follow‐up was 45 months. observed 60 (28.2%) pathological complete response (pCR). sequential...
The neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability predict disease-free survival (DFS) overall (OS) patients with luminal A- or B-HER2-negative cancer who received neoadjuvant chemotherapy (NACT). Pre-treatment complete blood cell counts from 168 consecutive were evaluated assess NLR. study population was stratified into NLRlow NLRhigh according cut-off value established by receiving operator curve (ROC)...
Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to a wide range of activity in hematologic malignancies cutaneous T-cell lymphoma multiple myeloma. Recent data show that they synergize with variety cytotoxic molecular targeted agents many different solid tumors, including breast, prostate, pancreatic, lung ovarian cancer. Hb-HDACIs quite good toxicity profile are now being tested phase I II clinical...
We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test.Median follow-up, length pertuzumab, trastuzumab maintenance 21, 4 15 months, respectively. The response rate was 77.3%, clinical benefit 93.6%. Median progression-free survival (mPFS) 21 median overall (mOS) not...
// Patrizia Vici 1 , Laura Pizzuti Isabella Sperduti 2 Antonio Frassoldati 3 Clara Natoli 4 Teresa Gamucci 5 Silverio Tomao 6 Andrea Michelotti 7 Luca Moscetti 8 Stefania Gori 9 Editta Baldini 10 Francesco Giotta 11 Alessandra Cassano 12 Daniele Santini 13 Diana Giannarelli Luigi Di Lauro Domenico Cristiano Corsi 14 Paolo Marchetti 15 Valentina Sini 15, 16 Sergi Maddalena Barba 1, 17 Marcello Maugeri-Saccà Michelangelo Russillo Lucia Mentuccia Loretta D'Onofrio Iezzi Angelo Fedele Scinto Da...
Abstract The inflammatory tissue microenvironment that promotes the development of breast cancer is not fully understood. Here we report a role for elevated IL30 in supporting cell viability and invasive migration. was absent normal mammary ducts, ductules, acini histologically scanty few stromal infiltrating leukocytes. In contrast, expressed frequently specimens where it associated with triple-negative HER2+ molecular subtypes. leukocytes found primary tumors or tumor-draining lymph nodes,...
Abstract Background There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and on first-line combinations are lacking. Method This was a real-world, multicenter, international, observational study determine the effects clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated immuno-oncology therapy. Results A total of 1827 mRCC from 71 cancer centers 21...
Abstract Data from 423 human epidermal growth factor receptor 2‐negative (HER2−), hormone receptor‐positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian centers analyzed for treatment outcomes. Overall, 158 in first line 265 second/later lines. We observed 19 complete responses 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) clinical benefit 52.7% CI,...
The aim of this study is to evaluate the long-term outcome patients with locally advanced breast cancer treated neoadjuvant systemic chemotherapy (NST) in routine clinical practice.Four hundred and nine were identified between January 1999 December 2011. All received NST followed by surgery, adjuvant treatments radiotherapy, as appropriate.At Kaplan-Meier analysis, surgical stage III disease more likely develop distant metastasis die from (p < 0.001). Luminal A luminal B/HER2-negative had...
Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated a observational study 102 postmenopausal, HR + HER2- metastatic patients treated with everolimus-exemestane first subsequent lines. Best overall response (BR) clinical benefit rate (CBR) assessed across subgroups defined upon fasting (FG) body mass index (BMI). Survival was estimated by Kaplan-Meier method...
Eribulin has shown survival advantage and manageable toxicity in heavily pre-treated metastatic breast cancer (mBC). We assessed whether body mass index (BMI) impacts treatment outcomes 101 patients treated with eribulin at six Italian Oncologic Centers. BMI was addressed as a categorical variable (18.5–24.9 vs. least 25). Clinical benefit rate (CBR) overall subgroups defined by BMI, line of therapy (LOT), hormone receptor (HR) status. Analysis CBR LOT HR status were further stratified BMI....
To characterize determinants of treatment outcome in a real world population 161 post-menopausal hormone receptor-positive metastatic breast cancer patients treated with fulvestrant. Descriptive statistics for demographics, anthropometrics, clinical and molecular characteristic were compared across subgroups sensitivity/resistance to prior endocrine therapy tested uni/multivariate models. Clinical benefit was more common sensitive higher estrogen receptor expression when fulvestrant given...
Response of cancer cells to chemotherapy-induced DNA damage is regulated by the ATM-Chk2 and ATR-Chk1 pathways. We investigated association between phosphorylated H2AX (γ-H2AX), a marker double-strand breaks that trigger cascade, Chk1 (pChk1), with pathological complete response (pCR) in triple-negative breast (TNBC) patients treated neoadjuvant chemotherapy. γ-H2AX pChk1 were retrospectively assessed immunohistochemistry series pretreatment biopsies related 66 patients. In fifty-three...
Aromatase inhibitors (AIs) are more effective than tamoxifen as neoadjuvant endocrine therapy (NET) for hormone receptor (HR)-positive breast cancer. Here we report the surgical and long-term outcome of elderly postmenopausal patients with locally advanced, HR-positive cancer treated preoperative AIs. Between January 2003 December 2012, 144 inoperable conservative surgery (BCS) received letrozole, anastrozole, or exemestane NET. Patients underwent adjuvant Adjuvant systemic therapy,...
To evaluate factors influencing the long-term outcome of patients presenting with 10 or more metastatic axillary lymph nodes (pN3a) after surgery for primary breast cancer.Between January 1990 and December 2015, a total 130 pN3a cancer at were identified in our Institutions included study. Twenty-nine them (22.3%) received neoadjuvant chemotherapy. The Multivariate Cox proportional hazards model was used to determine independent prognostic associated DFS OS.After median follow-up 6.4 years...
// Luca Moscetti 1, 8 , Maria Agnese Fabbri 1 Clara Natoli 2 Patrizia Vici 3 Teresa Gamucci 4 Isabella Sperduti 5 Laura Iezzi 6 Elena Iattoni Pizzuti Carmine Roma 7 Angela Vaccaro Giuliana D'Auria Mariella Mauri Lucia Mentuccia Antonino Grassadonia Maddalena Barba and Enzo Ruggeri Division of Medical Oncology, AUSL Viterbo, Belcolle Hospital Strada Sammartinese, 01100 Italy Department Medical, Oral Biotechnological Sciences CeSI-MeT University G. D'Annunzio, Chieti-Pescara, 66100 Chieti,...
Background The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy trastuzumab in this setting are available from randomized clinical trials. aims retrospective study were to assess how patients managed practice Italy, which or biological characteristics influenced choice adjuvant systemic therapy outcome patients. Methods Data consecutive who underwent surgery January 2007 December 2012 for HER2-positive, M0 retrospectively collected 28...
Body mass index (BMI) is largely investigated as a prognostic and predictive factor in triple-negative breast cancer (TNBC). Overweight obesity are linked to variety of pathways regulating tumor-promoting functions, including the DNA damage response (DDR). The DDR physiologically safeguards genome integrity but, neoplastic background, it aberrantly engaged protects cells from chemotherapy. We herein verified role BMI on previously assessed association between biomarkers pathological complete...